Vistagen announces completion of last patient, last visit in phase 2 clinical trial of ph94b for the treatment of adjustment disorder with anxiety

South san francisco, calif.--( business wire )--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that the last patient has completed the study protocol in its phase 2 clinical trial of ph94b for the treatment of adults experiencing adjustment disorder with anxiety (ajda).
VTGN Ratings Summary
VTGN Quant Ranking